Revenue
2020
2021
2022
2023
Hepion Pharmaceuticals, Inc. (HEPA)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2019
2020
2021
2022
2023
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 · Dec 31 | 2017 · Jun 30 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — |
| Research & development | $445,512 | $11.8M | $35.6M | $33.3M | $20.4M | $12.0M | $3.2M | $7.6M | $13.4M | $13.7M | $15.0M | $8.4M | $314,246 |
| Operating expenses | $4.2M | $19.3M | $48.4M | $45.5M | $30.4M | $20.1M | $7.8M | $14.6M | — | $21.0M | $20.8M | $14.0M | — |
| Operating income | −$4.2M | −$19.3M | −$48.4M | −$45.5M | −$30.4M | −$20.1M | −$7.8M | −$14.6M | −$20.6M | −$21.0M | −$20.8M | −$14.0M | −$1.7M |
| EBITDAderived | — | −$19.3M | −$48.4M | −$45.4M | −$30.3M | −$20.1M | −$7.7M | −$14.6M | — | −$21.0M | −$20.8M | −$13.9M | −$1.7M |
| Net income | −$8.3M | −$13.2M | −$48.9M | −$42.2M | −$32.7M | −$20.4M | −$7.0M | −$9.4M | — | −$14.9M | −$17.0M | −$14.3M | −$5.3M |
| Basic EPSper diluted share | -$0.88 | -$107.35 | -$616.07 | -$11.90 | -$0.47 | -$2.10 | -$5.95 | -$97.35 | — | -$2.04 | -$0.63 | -$1.02 | -$0.41 |
| Diluted EPSper diluted share | -$0.88 | -$107.35 | -$616.07 | -$11.90 | -$0.47 | -$2.10 | -$6.11 | -$1.39 | — | -$2.41 | -$0.63 | -$1.02 | -$0.41 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 21, 2026Form 4 | Purcell Michael J.Director | BuyCommon Stock, par value $0.0001 per share | 1.25M | $0.04 | $50.0K | 1.25M |
| Apr 21, 2026Form 4 | LoPriore Vincent SExecutive Chairman | BuyCommon Stock, par value $0.0001 per share · indirect | 1.25M | $0.04 | $50.0K | 6.25M |
| Apr 21, 2026Form 4 | LoPriore Vincent SExecutive Chairman | BuyCommon Stock, par value $0.0001 per share · indirect | 5.00M | $0.04 | $200.0K | 5.00M |
| Apr 21, 2026Form 4 | Appajosyula SireeshDirector | BuyCommon Stock, par value $0.0001 per share | 1.25M | $0.04 | $50.0K | 1.25M |
| Apr 21, 2026Form 4 | Stetz Gary S.Interim CEO | BuyCommon Stock, par value $0.0001 per share · indirect | 1.25M | $0.04 | $50.0K | 1.25M |